A Randomized Phase III Study of Palliative Radiation of Advanced Central Tumours With Intentional Avoidance of the Esophagus
A randomized phase II study of palliative radiation of advanced central lung tumours with
intentional avoidance of the esophagus. Patients will be randomized between standard of care
palliative thoracic radiation and esophageal-sparing intensity-modulated radiation therapy
(ES-IMRT) in a 1:1 ratio. Radiation Therapy will be administered as soon as possible following
randomization and subjects will be followed for 1 year after completion of their radiation
therapy. The primary endpoint is esophageal quality of life as measured by the Esophageal
Cancer Subscore (ECS) of the Functional Assessment of Cancer Therapy-Esophagus (FACT-E).
View this trial on ClinicalTrials.gov
Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.
These resources are provided in partnership with the
Canadian Cancer Society